S. Van Bruwaene MD, PhD, P. Dirix MD, PhD, H. Van Poppel MD, PhD
The prostate cancer (PCa) landscape has changed dramatically over the past few years. New paradigm-shifting data are published nearly every month. This review aims to give a brief overview of the most important publications of 2018–2019. From the ever-lasting discussion about PSA screening, with the recent publication of the CAP trial, over diagnostics where multi-parametric MRI has caused a true revolution, to hypofractionation in radiotherapy and the dramatic treatment shifts in metastatic hormone sensitive and non-metastatic castrate resistant PCa. All exciting data that will change clinical practice.
S. Van Bruwaene MD, PhD, B. Engels MD, PhD, B. Sautois MD, PhD
In line with the tradition, the BMUC scientific committee asked a urologist, a radiation oncologist and a medical oncologist to summarize the top stories that were presented during the large urology and oncology meetings of the past year.
B. Sautois MD, PhD, J.C. Goeminne MD, S. Rottey MD, PhD, D. Schrijvers MD, PhD, F. Van Aelst MD, S. Van Bruwaene MD, PhD, S. Watkins , A. Simmons , Jowell Go , Melanie Collins , T. Golsorkhi , W. Abida MD, PhD, C. Ryan , Howard Scher , S. Chowdhury